Nov 13 2014
RTI Surgical Inc.™ (RTI), a leading global surgical implant company, announced that The Journal of Spinal Disorders & Techniques published a study online highlighting nanOss® clinical data results. NanOss is an advanced bone graft substitute that is composed of nano-structured hydroxyapatite granules and an open structured engineered collagen carrier.
The Journal of Spinal Disorders & Techniques highlights peer-reviewed original articles on diagnosis, management and surgery for spinal issues. The study, published by the Journal online, is titled Use of Nanocrystalline Hydroxyapatite with Autologous BMA and Local Bone in the Lumbar Spine: A Retrospective CT Analysis of Posterolateral Fusion Results. Stephen E. Robbins, MD, orthopedic surgeon at Milwaukee Spinal Specialists, was the lead author on the study.
The study was comprised of a retrospective, multi-center, medical record review and independent analysis of CT scans that were performed in 46 patients. The 12-month postoperative CT scans determined radiographic arthrodesis rates after one-, two- or three-segment instrumented posterolateral fusions using autograft, BMA and a nanocrystalline hydroxyapatite bone void filler. The results showed that 94 percent of vertebral segments treated exhibited bilateral or unilateral posterolateral bridging bone.
NanOss’s multidimensional porosity is similar to human cancellous bone and provides a scaffold for the in-growth of new bone. It incorporates into the patient’s own newly-formed bone resulting in a fusion mass – the ultimate goal of any bone graft.
“The use of iliac crest autograft carries significant risk and creates a painful, secondary surgery site,” said Brian K. Hutchison, president and chief executive officer of RTI Surgical. “NanOss gives surgeons another bone growth option that has demonstrated equivalent fusion rates in the lumbar spine and provides an alternative for their patients. This study supports what we have heard from surgeons since the introduction of this product.”